Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Enanta Enters Into Strategic Collaboration With Novartis For EDP-239

RELATED NEWS
Trade NVS now with 

Private Equity Holding AG or PEH announced that a portfolio company Enanta Pharmaceuticals has entered into a strategic collaboration with Novartis AG (NVS: Quote) for the worldwide development, manufacture and commercialization of its lead development candidate, EDP-239, from its NS5A hepatitis C virus or HCV inhibitor program.

PEH is a minority shareholder and invested in Enanta in 1999 as part of the original shareholder syndicate.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks came under pressure in early trading on Friday and remained firmly in the red throughout the remainder of the trading session. With the losses on the day, the S&P 500 pulled back well off yesterday's record closing high. President Barack Obama is meeting with presidents from Central American nations on Friday as the U.S. struggles to deal with a surge of unaccompanied children across the southern border. Despite calls from some leading conservatives, the results of a new CNN/ORC International poll released Friday showed that a vast majority of Americans do not believe that President Barack Obama should be impeached and removed from office.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.